11 Hidden AI Stocks to Buy Right Now

4. GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Number of Hedge Fund Holders: 64

GE HealthCare Technologies Inc. (NASDAQ:GEHC) manufactures and markets products, services, and digital solutions for the diagnosis, treatment, and monitoring of patients. It operates through four segments. The company also provides new-age medical technology, cloud-first AI-enabled solutions, and data analytics services.

In Q1 2025, the company’s AVS (Advanced Visualization Solutions) segment reported revenue growth of 3% year-over-year, with particularly strong performance in the US. This growth, while currently a smaller portion of the overall $4.8 billion revenue, is important as GE HealthCare’s product roadmap for AVS is increasingly centered on accelerating recurring revenue through digital and AI-powered solutions across its ultrasound and Interventional Guided Therapy product portfolios.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is actively investing in R&D within the AVS segment to further advance its AI capabilities. On January 8, Jefferies analysts recently raised the stock’s rating from Hold to Buy due to a bullish outlook for the company. The analysts emphasized GE HealthCare’s ability to acquire market share in diagnostic imaging and prenatal diagnostics, which Jefferies regarded as increasing and under-modeled for future development.

Oakmark Fund stated the following regarding GE HealthCare Technologies Inc. (NASDAQ:GEHC) in its Q4 2024 investor letter:

“GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a leading global medical technology company that was spun off from General Electric in January 2023. As a standalone company, we expect GE HealthCare to benefit from increased focus, better aligned management and incentives, and an improved corporate culture. We believe these changes will help drive higher margins and organic growth. In addition, we think GE HealthCare is well-positioned to capitalize on technology trends as a greater portion of the value proposition comes from AI-enabled software and a shift toward precision care. A lack of appreciation for the company’s self-help potential coupled with short-term concerns around weak demand in China provided us with the opportunity to purchase shares at a low valuation relative to other high-quality medical technology companies and at the lowest price relative to the S&P 500 since the IPO.”